Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Resignation of Tanya Sanish as company secretary and compliance officer with effect from 20 February 2026.
Appointment of Pratibha Mishra (ACS No. 53432), as interim company secretary and compliance officer, KMP of the Company with effect from 21 February 2026.
Piramal Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 159.5, up 3.6% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.16% on the day, quoting at 25302.45. The Sensex is at 82334.29, down 0.01%. Piramal Pharma Ltd has dropped around 6.89% in last one month.
Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has dropped around 4.57% in last one month and is currently quoting at 21739.85, down 1.06% on the day. The volume in the stock stood at 132.69 lakh shares today, compared to the daily average of 30.98 lakh shares in last one month.
The benchmark February futures contract for the stock is quoting at Rs 157.79, up 2.3% on the day. Piramal Pharma Ltd is down 31.03% in last one year as compared to a 8.83% gain in NIFTY and a 0.42% gain in the Nifty Pharma index.
The PE of the stock is 29.05 based on TTM earnings ending September 25.
Piramal Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 157.07, down 0.47% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.07% on the day, quoting at 25214.4. The Sensex is at 82152.2, down 0.03%.Piramal Pharma Ltd has eased around 11.61% in last one month.Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has eased around 5.58% in last one month and is currently quoting at 21714.3, down 0.31% on the day. The volume in the stock stood at 23.5 lakh shares today, compared to the daily average of 30.73 lakh shares in last one month.
The benchmark January futures contract for the stock is quoting at Rs 156.7, down 0.88% on the day. Piramal Pharma Ltd tumbled 35.18% in last one year as compared to a 8.89% rally in NIFTY and a 1.76% fall in the Nifty Pharma index.
The PE of the stock is 29.71 based on TTM earnings ending September 25.
The company is preparing a detailed response to be submitted within the stipulated timelines and said it remains committed to the highest standards of compliance, working closely with the regulator to address all points raised.
Piramal Pharma (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, selling over-the-counter products.
The company reported a consolidated net loss of Rs 99.22 crore in Q2 FY26, compared with a net profit of Rs 22.59 crore recorded in Q2 FY25. Revenue from operations for the period under review declined 8.83% year-on-year (YoY) to Rs 2,043.72 crore.
Shares of Piramal Pharma rose 0.93% to Rs 173.40 on the BSE.
Piramal Pharma Ltd is down for a fifth straight session today. The stock is quoting at Rs 193, down 1.25% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.14% on the day, quoting at 25609.05. The Sensex is at 83614.62, up 0.09%.Piramal Pharma Ltd has lost around 2.32% in last one month.Meanwhile, Nifty Pharma index of which Piramal Pharma Ltd is a constituent, has increased around 0.57% in last one month and is currently quoting at 22379.85, down 0.22% on the day. The volume in the stock stood at 12.78 lakh shares today, compared to the daily average of 35.33 lakh shares in last one month.
The benchmark November futures contract for the stock is quoting at Rs 193.39, down 1.49% on the day. Piramal Pharma Ltd tumbled 22.98% in last one year as compared to a 7.23% rally in NIFTY and a 0.81% spurt in the Nifty Pharma index.
The PE of the stock is 36.8 based on TTM earnings ending September 25.
Realty shares tumbled for second consecutive trading session.
At 14:25 IST, the barometer index, the S&P BSE Sensex declined 47.59 points or 0.06% to 83,419.87. The Nifty 50 index fell 62.95 points or 0.25% to 25,534.40.
The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index declined 1.33% and the S&P BSE Small-Cap index fell 0.47%.
The market breadth was weak. On the BSE, 1,188 shares rose and 2,960 shares fell. A total of 167 shares were unchanged.
Economy:
The seasonally adjusted HSBC India Services PMI Business Activity Index stood at 58.9 in October, comfortably above both the neutral mark of 50.0 and its long-run average of 54.3. October data showed softer, although still substantial, expansions in Indian services output and new business. While factors like demand buoyancy and GST (Goods and Services Tax) relief reportedly led to an improvement in operating conditions, competition and heavy rains constrained growth.
HSBC India Composite PMI Output Index fell to 60.4 in October from 61.0 in September. There was also a weaker, albeit still substantial, upturn in aggregate sales. The rate of expansion was the softest in five months. For new orders and output, the slowdowns in growth were centred on the service economy as manufacturers actually registered quicker rates of expansion.
Buzzing Index:
The Nifty Realty index fell 1.27% to 948.85. The index dropped 2.04% in the two consecutive trading sessions.
Anant Raj (down 3.49%), Godrej Properties (down 3.45%), Brigade Enterprises (down 2.46%), DLF (down 2.03%), Prestige Estates Projects (down 1.31%), Phoenix Mills (down 1.24%) and Oberoi Realty (down 0.02%) declined.
Numbers to Track:
The yield on India's 10-year benchmark federal paper shed 0.47% to 6.499 from the previous close of 6.530.
In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 88.6400 compared with its close of 88.7700 during the previous trading session.
MCX Gold futures for 5 December 2025 settlement rose 0.71% to Rs 121,376.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.15% to 100.02.
The United States 10-year bond yield fell 0.38% to 4.143.
In the commodities market, Brent crude for December 2025 settlement advanced 34 cents or 0.54% to $63.86 a barrel.
Stocks in Spotlight:
Devyani International (DIL) declined 2.105 after the company reported a mixed Q2 FY26 performance, with net loss widening to Rs 23.95 crore from Rs 4.92 crore in Q2 FY25, despite revenue growth driven by network expansion and steady demand. On a consolidated basis, revenue from operations increased 12.7% year-on-year to Rs 1,376.75 crore in the quarter ended September 2025.
Indoco Remedies fell 1.70%. The company consolidated net loss narrowed to Rs 9.21 crore in Q2 FY26, compared with net loss of Rs 10.01 crore reported in Q2 FY25. Revenue from operations stood at Rs 471.83 crore in the second quarter of FY26, up 9.59% as against Rs 430.66 crore posted in Q2 FY25.
Piramal Pharma rose 0.92%, The company reported a consolidated net loss of Rs 99.22 crore in Q2 FY26, compared with a net profit of Rs 22.59 crore recorded in Q2 FY25. Revenue from operations for the period under review declined 8.83% year-on-year (YoY) to Rs 2,043.72 crore. The YoY performance was impacted by inventory destocking by a customer in one large CDMO order.